Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Multicenter Dose Escalation and Multiple Cohort Expansion Phase 1a/b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ADCX-020 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT07238075 is registered in ClinicalTrials.gov with Adcytherix SAS as lead sponsor.

NCT NCT07238075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07238075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Multicenter Dose Escalation and Multiple Cohort Expansion Phase 1a/b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ADCX-020 in Participants With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Adcytherix SAS
Phase
Phase 1
Overall status
Recruiting
Start date
February 23, 2026
Completion date
November 30, 2029
Enrollment
290 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancy, advanced solid cancers, metastatic solid tumors